Results from Preclinical and Clinical Studies Demonstrate Activity of
Investigational Agent against Gram-Positive Bacteria
CHICAGO, Sept. 18 /PRNewswire/ -- Astellas Pharma US, Inc. and Theravance, Inc. (Nasdaq: THRX) announced today results with the investigational compound telavancin from the largest subset of surgical-site-associated complicated skin and skin structure infections (cSSSIs) from a controlled Phase 3 clinical program in patients with complicated Gram-positive cSSSIs, and results from preclinical and surveillance studies were recently presented at the 47th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Chicago, Illinois.
Telavancin is a novel lipoglycopeptide injectable antibiotic discovered by Theravance that was engineered to have a unique, multifunctional mechanism of action; it inhibits the formation of the bacterial cell wall and disrupts bacterial cell membrane function. Telavancin is currently being evaluated by regulatory authorities in the United States and Europe for its safety and efficacy in the treatment of complicated skin and skin structure infections and is in Phase 3 studies for the treatment of hospital-acquired pneumonia.
The following clinical activity of telavancin was reported at ICAAC.
New data from an analysis of a subset of nearly 200 patients with
surgical-site-associated complicated skin and skin structure infections
(cSSSIs) suggest that once-daily telavancin is clinically active in
surgical-site-associated cSSSIs due to Staphylococcus aureus, including
methicillin-resistant Staphylococcus aureus (MRSA). These data are from the
ATLAS (Assessment of TeLAvancin in complicated Skin and skin structure
|SOURCE Astellas Pharma US, Inc.|
Copyright©2007 PR Newswire.
All rights reserved